Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
16.7 USD | -0.24% | -3.03% | -46.76% |
Apr. 23 | Neuren Pharmaceuticals' Medication Secures Priority Review from Health Canada | MT |
Apr. 22 | Acadia Pharmaceuticals' Rett Syndrome Treatment Granted Priority Review by Health Canada | MT |
- Stock Market
- Equities
- ACAD Stock
- News ACADIA Pharmaceuticals Inc.